两种化疗方案治疗晚期非小细胞肺癌的Meta分析

目的：比较吉西他滨、长春瑞滨联合顺铂治疗晚期非小细胞肺癌的缓解率、一年生存率与毒性反应。方法：检索Pubmed数据库和CHKD数据库，纳入随机对照试验，用专用软件Review Manager version4．2．2进行系统评价。结果：共有8个研究1741例患者纳入系统评价，吉西他滨＋顺铂方案与长春瑞滨＋顺铂方案在总缓解率和一年生存率上无区别，吉西他滨＋顺铂方案中性粒细胞减少发生率低于长春瑞滨＋顺铂方案，血小板减少发生率高于长春瑞滨＋顺铂方案，恶心呕吐发生率与神经系统反应两者差异无统计学意义。结论：在晚期非小细胞肺癌治疗中，吉西他滨联合顺铂与长春瑞滨联合顺铂疗效相似，在毒性反应方面各有利弊，应结合患者具体情况，选择对患者生活质量影响较小的方案。

Meta-Analysis of two combined chemotherapy for Advanced Non-small Cell Lung Cancer

Objective： To compare and evaluate the effectiveness bine combined with cisplatin of advanced non-small cell lung cancer.1 -year survival rate and toxicities of gemcitabine versus vinorel- Method： Pubmed database and CHKD database were searched, included in randomized controlled trials, special software Review Manager version 4.2.2 was used of meta-analysis for systematic reviews. Result： Eight studies involving 1 741 patients were included. There was no different in the overall response and 1-year survival rate from gemeitabine versus vinorelbine in combination with eisplatin. The incidence rate of neutropenia was higher in vinorelbine ＋ cisplatin, and the thrombocytopenia was higher in gemcitabine ＋ cisplatin, nausea and vomiting and nervous system response was no significant difference between the two groups. Conclusion ： In advanced non-small cell lung cancer patients, gemcitabine plus cisplatin and vinorelbine combined with cisplatin is similar to efficacy and the toxic reactions have their own advantages and disadvantages.